MDM2 as a predictor of prostate carcinoma outcome: An analysis of radiation therapy oncology group protocol 8610

Li Yan Khor, Michelle DeSilvio, Tahseen Al-Saleem, M. Elizabeth Hammond, David J. Grignon, William Sause, Michael Pilepich, Paul Okunieff, Howard Sandler, Alan Pollack

Research output: Contribution to journalArticle

45 Scopus citations

Abstract

BACKGROUND. The MDM2 oncoprotein promotes p53 degradation via ubiquitin, establishing negative feedback control of p53 and consequently affecting cell cycle arrest and apoptosis. The authors evaluated the association between MDM2 expression and local failure, distant metastasis (DM), cause-specific mortality, and overall mortality in men treated in Radiation Therapy Oncology Group 8610 with radiotherapy, with or without androgen deprivation. METHODS. Of the 456 eligible and analyzable patients (parent cohort), adequate archival diagnostic tissue specimens from 108 patients were available for MDM2 analysis (MDM2 cohort). Cox proportional hazards multivariate analysis (MVA) was used to determine the relation of MDM2 to the endpoints. MDM2 overexpression was manually classified as > 5% nuclear staining. An image analysis system was also used to quantify the proportion of tumor nuclei with MDM2 staining (ACIS index) and staining intensity. RESULTS. Overexpression of MDM2 by manual counts was seen in 44% (n = 47) of the patients. In the manual count analysis, there was no significant relation between MDM2 overexpression and outcome. The ACIS index, using a cutoff point defined by the median value, ≤ 3% versus > 3%, was related to 5-year DM rates in univariate analyses (32.6% vs. 45.8%; P = 0.057) and MVA (P = 0.06). The intensity of MDM2 staining was not significant. CONCLUSIONS. MDM2 expression quantified by image analysis was weakly associated with DM. The cohort examined was relatively small and with larger patient numbers, MDM2 overexpression may emerge as a more significant covariate.

Original languageEnglish (US)
Pages (from-to)962-967
Number of pages6
JournalCancer
Volume104
Issue number5
DOIs
StatePublished - Sep 1 2005

Keywords

  • Androgen deprivation
  • Distant metastasis
  • MDM2
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'MDM2 as a predictor of prostate carcinoma outcome: An analysis of radiation therapy oncology group protocol 8610'. Together they form a unique fingerprint.

  • Cite this

    Khor, L. Y., DeSilvio, M., Al-Saleem, T., Hammond, M. E., Grignon, D. J., Sause, W., Pilepich, M., Okunieff, P., Sandler, H., & Pollack, A. (2005). MDM2 as a predictor of prostate carcinoma outcome: An analysis of radiation therapy oncology group protocol 8610. Cancer, 104(5), 962-967. https://doi.org/10.1002/cncr.21261